| 摘要: |
| 伊立替康是喜树碱衍生物,属于拓扑异构酶I抑制剂,具有广谱的抗肿瘤作用。在临床应用中,无论单药使用还是联合其它药物治疗癌症,都取得了较好的效果。由于药物的半衰期短以及严重的毒副作用,限制了伊立替康在临床上的应用。伊立替康新型载药系统具有缓释作用,可进一步提高药物的生物利用度,同时降低毒副作用,因此成为近年来国内外学者的研究热点。本文主要介绍伊立替康在纳米粒、脂质体和微球等新型载药系统的研究进展。 |
| 关键词: 伊立替康 纳米粒 脂质体 微球 载药系统 |
| DOI:10.13506/j.cnki.jpr.2019.08.013 |
| 基金项目: |
|
|
|
| Research progress on novel drug delivery systems of Irinotecan |
| SUI Jiying,GAO Cong,DOU Mingjin |
| (Affiliated Hospital of Shandong Academy of Medical Science,Jinan 250031,China) |
| Abstract: |
| Irinotecan is a camptothecin derivative belonging to the topoisomerase I inhibitors,which has broad-spectrum antitumor activities.In clinical applications both single drug treatment and multiple chemotherapy of irinotecan have achieved good therapeutic effects.However, disadvantages of irinotecan,such as short half-life and poor biocompatibility have limited its widely clinical use.Novel drug delivery systems which with high bioavailability and low side effects have become the focus in recent years.The article summarized the research progress of irinotecan on the new drug carriers,such as nanoparticles,liposomes and microspheres. |
| Key words: Irinotecan Nanoparticles Liposomes Microspheres Drug delivery system |